Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer

摘要

Background/Aim: There is no definitive biomarker that predicts the effectiveness of abiraterone acetate. The objective of this study was to investigate whether dehydroepiandrosterone sulfate (DHEA-S) predicts the effectiveness of abiraterone acetate. Materials and Methods: This study included a total of 28 consecutive patients. The optimal cutoff value of DHEA-S for predicting the PSA response was calculated by receiver operating characteristic (ROC) analysis. The Cox proportional hazards model was performed to determine the predictive factors for the susceptibility to abiraterone acetate. Results: Serum DHEA-S at baseline intercorrelated with the PSA response (correlation coefficient: -0.516). The optimal cutoff value of serum DHEA-S at baseline was 47.4 ug/dl in predicting 50% PSA decline. Serum PSA and serum DHEA-S at baseline were identified as significant factors for predicting PSA progression free survival (p=0.010 and p=0.003, respectively). Conclusion: Serum DHEA-S at baseline may be a biomarker for predicting the prognosis of CRPC patients treated with abiraterone acetate.